§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4388306A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical composition comprising modified polyriboinosinic-polyribocytidylic acid, for induction of interferon in primates

Assignee: Merck and Co Inc
•
Filing: 1982-02-08
•
Granted: 1983-06-14
•
Expires: 2002-02-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A complex of polyriboinosinic-polyribocytidylic acid (poly I:C) with poly-L-lysine hydrobromide ([lysine.HBr]n) having a defined molecular weight is prepared which is about 5-15 times as resistant to hydrolysis by pancreatic ribonuclease as the parent poly I:C. A pharmaceutical solution, containing a relatively high concentration of the complex, prepared as described, induces significant antiviral levels of serum interferon in monkeys under conditions in which poly I:C itself induces little or no interferon. An important feature of this invention is that the product is a soluble material requiring no special solubilizing agent, thereby facilitating the preparation of solutions having the desired concentration. The product will hereinafter be designated as poly I:C/poly-L-lysine.

Inventors

  • 👤 A. Kirk Field
  • 👤 Alfred A. Tytell
  • 👤 George P. Lampson

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 08:04
CPC Classifications
C; C07; C07H; C07H21/00; A; A61; A61K; A61K31/00; A61K31/74; A61K31/785; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/29

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 117 words
An interferon-inducing composition comprising a solution in a pharmaceutically acceptable aqueous carrier, of a complex of poly I:C/poly-L-lysine hydrobromide or hydrochloride, the concentration in solution of the poly I:C being from about 1 to about 2 mg/ml, the ratio by dry weight of the poly I:C to the poly-L-lysine hydrobromide or hydrochloride being about 1 to about 0.3, or a molar ratio of 2:1; the poly I having a S w 20° of 11-20, and an E 1% at 248 nm of 240-280; the poly C having a S w 20° of 5-7 and an E 1% at 248 nm of 175-185; and the poly-L-lysine having a molecular weight of from about 10,000 to about 70,000 daltons.
Claim 2
Dependent Claim 117 words
An interferon-inducing composition comprising a solution in a pharmaceutically acceptable aqueous carrier, of a complex of poly I:C/poly-L-lysine hydrobromide or hydrochloride, the concentration in solution of the poly I:C being from about 1 to about 2 mg/ml, the ratio by dry weight of the poly I:C to the poly-L-lysine hydrobromide or hydrochloride being about 1 to about 0.3, or a molar ratio of 2:1; the poly I having a S w 20° of 11-20, and an E 1% at 248 nm of 240-280; the poly C having a S w 20° of 5-7 and an E 1% at 248 nm of 175-185; and the poly-L-lysine having a molecular weight of from about 10,000 to about 70,000 daltons.
Claim 3
Dependent Claim 15 words
The composition of claim 1 in which the poly I:C concentration is about 1 mg/ml.
Claim 4
Dependent Claim 14 words
The composition of claim 1 in which the poly-L-lysine is in the hydrobromide form.
Claim 5
Dependent Claim 22 words
The composition of claim 3 in which the molecular weight of the poly-L-lysine hydrobromide is from about 10,000 to about 35,000 daltons.
Claim 6
Dependent Claim 26 words
The composition of claim 1 wherein the poly I has a S w 20° of about 19 and an E 1% at 248 nm of 240.
Claim 7
Dependent Claim 24 words
The composition of claim 1 wherein poly C has a S w 20° of about 5 and an E 1% at 248 of 177.

References Cited (Backward Citations)

US3679654A Cited
US3725545A Cited
US4024222A Cited
US4130641A Cited
US3952097A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-06-13 1986-12-13 1987-06-14 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-06-13 1990-12-13 1991-06-14 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-06-13 1994-12-13 1995-06-14 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag